Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coviracil license dispute

Executive Summary

Glaxo Wellcome grants full emtricitabine development rights to Triangle and Emory University under a legal dispute settlement, Triangle announced May 7. Discovered by Emory scientists, the antiviral nucleoside analogue for the treatment of HIV and hepatitis B was originally licensed to Burroughs-Wellcome. Most rights to Coviracil (formerly FTC) were returned to Emory when Glaxo acquired Burroughs-Wellcome, and were subsequently licensed to Triangle ("The Pink Sheet" April 27, 1998, p. 23). Emtricitabine is in the same class as Glaxo/BioChem's Epivir (lamivudine). The dispute settlement shifts Glaxo's remaining Coviracil property rights to Triangle, which is currently conducting Phase II/III trials in HIV and Phase I/II trials in HBV
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS034117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel